These results are supported by our previous data, which showed that the addition of a CXCR4 inhibitor (AMD3100) abrogated the CXCL12-induced phosphorylation of mitogen-activated protein kinase (MEK)1/2 in cholangiocarcinoma cells (16). Here, MAP2K1 is linked to cholangiocarcinoma.